Immunity is more than just neutralizing antibodies.
Why? Because MOST of your T-cell responses from vaccination or previous infection STILL recognize Omicron.
Let’s talk about that!🧵
Immunological memory consists of antibodies, memory B-cells, memory CD8+ T-cells, and memory CD4+ T-cells. These responses are what give us enduring protection even against newly emerging SARS-CoV-2 variants.
Immunological memory is probably the most important feature of immunity as it allows us to better respond when the threat is encountered a second time. Against SARS-CoV-2, it helps to determine protection against reinfection, disease risk, and vaccine efficacy.
As long as your T-cells still recognize this virus and inform your B-cells they need to get to work and adjust to make antibodies to be better “fit” you’re protected. Imagine your B-cells are your sword that need sharpening every now and again and your T-cells are your shield.
The term infection refers to the virus entering and being detectable in your system regardless of whether OR NOT it makes you sick, whereas the term illness refers to the virus entering, being detectable in your system AND making you sick. It it important not to conflate the two.
T-cell epitopes in natural infection? Their analysis of the full proteome here showed that on average 98% of CD8+ and 95% of CD4+ epitopes were totally conserved.
T-cell epitopes and vaccination? Here is the analysis of spike-only data. Since many variant mutations are in spike, naturally a higher number of mutated T-cell epitopes. On average 94% of CD8+ and 91% of CD4+ epitopes were still totally conserved.
When they get to Omicron presumably because of the higher number of mutations, the fraction of CD8+ epitopes that are 100% conserved drops significantly to 95% for CD8+ and 88% for CD4+ whole proteome. Guess what? Still VERY HIGH conservation.
“Despite Omicron's extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T-cell response, induced by vaccination or natural infection, cross-recognises the variant.”
•medrxiv.org/content/10.110…
•
Researchers here assessed the ability of T-cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients. They found that 70-80% of the CD4+ and CD8+ T-cell response to spike was maintained.
Moreover, the magnitude of Omicron cross-reactive T-cells was similar to that of the Beta and Delta variants, DESPITE Omicron harbouring considerably more mutations.
Indeed, South Africa has reported a lower risk of hospitalization and severe disease compared to the previous Delta wave. Cross-reactive T-cell responses acquired through vaccination or infection may contribute to these apparent milder outcomes for Omicron.
You can read more here papers.ssrn.com/sol3/papers.cf… and reuters.com/business/healt…. The resilience of T-cell response demonstrated here also bodes well in the event that more highly mutated variants emerge in the future. MAKE SURE YOU ARE PROTECTED. DON’T WALK AROUND IMMUNE NAIVE.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
THIS IS HUGE! An HIV PrEP drug candidate in the form of a twice-yearly subcutaneous injection has been shown to reduce HIV infections by 96% in a SECOND late-stage Phase III trial. Lenacapavir was 99.9% effective at preventing HIV in MORE THAN 2,000 participants.🧵⬇️
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
So, not COVID related BUT, this is REALLY exciting news. Phase I/II data shows Moderna’s Norovirus vaccine candidate mRNA-1403, has shown early signs of efficacy AND elicited robust serum HBGA-blocking antibody responses against ALL THREE NoV genotypes. Let’s talk about that!🧵⬇️
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomized, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden. Symptoms include vomiting and diarrhoea, which can be severely dehydrating, and the risk of severe outcomes from NoV is greatest in young children and older
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that!🧵⬇️
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧵⬇️
Tau proteins are essential for maintaining the structure and function of neurons. However, in Alzheimer’s disease, these proteins malfunction and aggregate into long, twisted fibrils. As these fibrils build up, they form neurofibrillary tangles- masses of tangled tau proteins
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧵⬇️
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals-
THIS IS HUGE! Scientists at the University of Oxford are developing the world's FIRST ovarian cancer vaccine that could potentially wipe the disease out. OvarianVax teaches the immune system to recognize and attack the earliest stages of ovarian cancer. Let’s talk about that!🧵⬇️
The hope is that individuals could receive the vaccine preventatively with the goal of eradicating the disease. Researchers have suggested it could work in a similar way to the human papillomavirus (HPV) vaccine, which is on track to stamp out cervical cancer.
Oxford researchers are designing OvarianVax, a vaccine which teaches the immune system to recognize and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.